US IPO Preview | Mask Dividend Fades + Health Supplements Stall: Lico International's IPO Breakout Battle

Title context: US IPO Preview | Mask Dividend Fades + Health Supplements Stall: Lico International's IPO Breakout Battle Text: At a time when demand for pandemic-prevention supplies has become normalized and the valuation of medical consumables is returning to cash flow and channel capabilities, medical-grade mask manufacturer Top Leader Universal is heading to the capital market. Recently, Top Leader Universal publicly submitted an F-1 prospectus to the U.S. Securities and Exchange Commission (SEC), applying for a listing on the OTCQB market. It plans to issue 2.5 million shares at $1.5 per share, aiming to raise approximately $3.75 million. It is worth noting that Top Leader Universal is trying to tell a story that is not just about masks, but about a full-chain closed loop from raw material procurement, cleanroom production, packaging and quality inspection to five categories of terminal distribution, extending to a multi-brand matrix including TL Gloves, TL Clean, TL Beauty, Calipro, and others. Can this model truly create synergistic premium, or does it remain merely at the level of a business patchwork? The following will break it down one by one. Performance growth appears lackluster Operating cash flow rises against the trend The prospectus shows that Top Leader Universal is based in Hong Kong, and its brand TL Mask focuses on medical-grade masks. It has an ISO Class 8 cleanroom, more than 23 production lines, and has obtained certifications such as ASTM Level 3, EN14683 IIR, and CE, with filtration efficiency exceeding 99%. These qualifications constitute a "compliance entry ticket" to hospitals, pharmacies, and European export markets, but certification barriers are not equivalent to pricing power. For low-value medical consumables companies, what the capital market cares about more is whether production capacity can be converted into sustained revenue, whether channels can bring repeat purchases, and whether profits can remain resilient amid raw material fluctuations and expense investments. Through its 2024 and 2025 income statements and cash flow statements, we can clearly see that beneath the appearance of near-stagnant revenue growth, the company is facing pressure from declining gross margin. Top Leader Universal's revenue in 2024 and 2025 was $3.7132 million and $3.7220 million, respectively, a year-on-year increase of only 0.24%. With the capacity endorsement of more than 23 production lines and an ISO Class 8 cleanroom, revenue growth of nearly zero directly reflects that its core mask business has reached a demand ceiling. The pandemic-driven dividend for pandemic-prevention supplies has completely receded, and the industry has entered a stage of stock competition, lacking the explosive power of a second growth curve. More severe is the pressure on its profitability. The company's gross profit fell from $2.0940 million in 2024 to $2.0119 million in 2025, a decrease of 3.9%; gross margin declined from 56.4% to 54.1%. The core reason for the decline in gross profit was the rise in cost of revenue: third-party cost of revenue increased by 7.8% year over year, and although related-party costs fell by 14.2%, they failed to offset the overall rise in costs. With limited room to raise prices for terminal products, fluctuations in raw material prices and marginal changes in capacity utilization are continuously squeezing profit space. Worth noting is the structural anomaly in operating expenses. In 2025, the company's selling expenses (third-party) plunged 45.2% to $128,900, while general and administrative expenses (third-party) surged 64.0% to $806,400, forming a scissors gap of "one down, one up." Ultimately, total operating expenses in 2025 increased 25.6% year over year, directly causing income before income taxes to fall 23.8% year over year, and net profit to plummet from $1.0731 million to $778,400, a drop of as much as 27.5%. However, compared with the bleak income statement, the cash flow statement presents a different picture. In 2025, net cash provided by operating activities reached $745,100, a sharp increase of 74.8% from $426,300 in 2024. Against the backdrop of a sharp decline in net profit, operating cash flow rose against the trend, which usually means that changes in working capital (inventory, accounts receivable, accounts payable) released cash. In summary, Top Leader Universal's zero revenue growth and cliff-like decline in net profit indicate that its core mask business has lost its high-growth engine, and the improvement in operating cash flow also does not appear to be a restoration of endogenous profitability. At a time when the overall valuation of the medical consumables sector is correcting and the market prefers assets with stable cash flow and high certainty of growth, if Top Leader Universal cannot provide a feasible path to break through the revenue bottleneck, its issue pricing may face pressure. Breaking through with a "full-chain closed loop" Can the second growth curve breakout battle work? In order to find a second growth curve, Top Leader Universal has begun to tell a growth logic story centered on a "full-chain closed loop." Is this closed-loop logic a "moat" supporting a higher valuation, or a "blind box" that distracts energy? From the financial data, Top Leader Universal's revenue base remains solid. In 2025, revenue from self-manufactured mask products reached $3.5623 million, up 3.1% year over year, accounting for as much as 95.7% of total revenue. This slight increase may look mediocre, but against the backdrop of normalized global mask demand and severe overcapacity in the industry, being able to stabilize its base with ISO Class 8 cleanroom certification and stringent qualifications such as ASTM Level 3 and EN14683 IIR is already not easy. This shows that its "medical-grade" positioning has strong customer stickiness in B-end hospital and pharmacy channels. However, the second growth curve that had been highly anticipatedhealth supplement salessuffered a heavy setback in 2025, with revenue plunging 37.9% from $257,000 the previous year to $159,700, accounting for less than 5%. This structure of "slight growth in the main business and stalling in the side business" constitutes Top Leader Universal's current hidden concern. In the prospectus, the company explicitly proposed to "shift more resources to the nutritional products market," aiming to offset the expected decline in mask sales through product diversification. However, judging from performance, this strategic transformation does not appear to have been very successful. It is worth mentioning that on the manufacturing side, Top Leader Universal's strategic planning demonstrates a strong industrial gene. The company plans to further increase daily production capacity from the current 150,000 masks by purchasing new mask production machines and upgrading existing automation components. In the low-value medical consumables sector, homogenized competition is intense, and the room for price increases in terminal products is extremely limited, so the core competitiveness of enterprises lies in cost control. Better production speed, higher precision, and reliability brought by new machines, combined with the replacement of manual monitoring stations by automation components, will directly reduce unit production costs and improve operating efficiency. At the same time, the expansion of production capacity enables it to comfortably handle larger order volumes during peak demand periods, which is crucial for undertaking large overseas OEM orders and expanding into international markets. It can be said that the closed loop on the manufacturing side builds a baseline defense for Top Leader Universal of "trading volume for price and safeguarding profits through efficiency." However, diversification on the product side is ultimately the most imaginative part of Top Leader Universal's full-chain closed loop. The company plans to develop enhanced-function masks for different face shapes and different industry environments (such as extended wearing comfort), and use the brand matrix of TL Gloves (gloves), TL Clean (disinfection), TL Beauty (skincare), and Calipro (health supplements) to extend its product line from single-category medical protection to the broader health consumption field. If this synergy can be made to work, the company's market positioning will upgrade from a "multi-functional mask supplier" to a "comprehensive healthcare provider," thereby breaking the ceiling of the mask market and achieving a reconstruction of its valuation logic. But it should be noted that health supplements and skincare products, which have stronger consumer attributes, have marketing methods completely different from the B-end centralized procurement and pharmacy distribution of medical consumables, which poses a severe test for the company's brand operation capabilities. Taken together, Top Leader Universal's "full-chain closed loop" strategy is an active defense and proactive breakout in response to its current operating difficulties. However, the capital market's gaze is always cautious. Strategic narratives must ultimately be realized in financial performance. At present, if Top Leader Universal wants to complete a thrilling leap through an IPO, it must prove to investors that its full-chain closed loop can bring positive operating cash flow, rather than merely being blind expansion of its business map.